These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 32382048)
1. Isocitrate dehydrogenase (IDH) status prediction in histopathology images of gliomas using deep learning. Liu S; Shah Z; Sav A; Russo C; Berkovsky S; Qian Y; Coiera E; Di Ieva A Sci Rep; 2020 May; 10(1):7733. PubMed ID: 32382048 [TBL] [Abstract][Full Text] [Related]
2. Structural- and DTI- MRI enable automated prediction of IDH Mutation Status in CNS WHO Grade 2-4 glioma patients: a deep Radiomics Approach. Yuan J; Siakallis L; Li HB; Brandner S; Zhang J; Li C; Mancini L; Bisdas S BMC Med Imaging; 2024 May; 24(1):104. PubMed ID: 38702613 [TBL] [Abstract][Full Text] [Related]
3. Generative AI in glioma: Ensuring diversity in training image phenotypes to improve diagnostic performance for IDH mutation prediction. Moon HH; Jeong J; Park JE; Kim N; Choi C; Kim YH; Song SW; Hong CK; Kim JH; Kim HS Neuro Oncol; 2024 Jun; 26(6):1124-1135. PubMed ID: 38253989 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting. Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040 [TBL] [Abstract][Full Text] [Related]
5. Diffusion- and perfusion-weighted MRI radiomics model may predict isocitrate dehydrogenase (IDH) mutation and tumor aggressiveness in diffuse lower grade glioma. Kim M; Jung SY; Park JE; Jo Y; Park SY; Nam SJ; Kim JH; Kim HS Eur Radiol; 2020 Apr; 30(4):2142-2151. PubMed ID: 31828414 [TBL] [Abstract][Full Text] [Related]
7. Machine learning reveals multimodal MRI patterns predictive of isocitrate dehydrogenase and 1p/19q status in diffuse low- and high-grade gliomas. Zhou H; Chang K; Bai HX; Xiao B; Su C; Bi WL; Zhang PJ; Senders JT; Vallières M; Kavouridis VK; Boaro A; Arnaout O; Yang L; Huang RY J Neurooncol; 2019 Apr; 142(2):299-307. PubMed ID: 30661193 [TBL] [Abstract][Full Text] [Related]
8. An Intra- and Inter-Modality Fusion Model Using MR Images for Prediction of Glioma Isocitrate Dehydrogenase (IDH) Mutation. Shi X; Zhang X; Iwamoto Y; Cheng J; Bai J; Zhao G; Chen YW Annu Int Conf IEEE Eng Med Biol Soc; 2022 Jul; 2022():198-202. PubMed ID: 36086447 [TBL] [Abstract][Full Text] [Related]
9. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348 [TBL] [Abstract][Full Text] [Related]
10. Multivariable non-invasive association of isocitrate dehydrogenase mutational status in World Health Organization grade II and III gliomas with advanced magnetic resonance imaging T2 mapping techniques. Kern M; Auer TA; Fehrenbach U; Tanyildizi Y; Picht T; Misch M; Wiener E Neuroradiol J; 2020 Apr; 33(2):160-168. PubMed ID: 31957551 [TBL] [Abstract][Full Text] [Related]
11. Generative adversarial network for glioblastoma ensures morphologic variations and improves diagnostic model for isocitrate dehydrogenase mutant type. Park JE; Eun D; Kim HS; Lee DH; Jang RW; Kim N Sci Rep; 2021 May; 11(1):9912. PubMed ID: 33972663 [TBL] [Abstract][Full Text] [Related]
12. Identification of IDH and TERTp mutations using dynamic susceptibility contrast MRI with deep learning in 162 gliomas. Buz-Yalug B; Turhan G; Cetin AI; Dindar SS; Danyeli AE; Yakicier C; Pamir MN; Özduman K; Dincer A; Ozturk-Isik E Eur J Radiol; 2024 Jan; 170():111257. PubMed ID: 38134710 [TBL] [Abstract][Full Text] [Related]
13. A novel fully automated MRI-based deep-learning method for classification of IDH mutation status in brain gliomas. Bangalore Yogananda CG; Shah BR; Vejdani-Jahromi M; Nalawade SS; Murugesan GK; Yu FF; Pinho MC; Wagner BC; Mickey B; Patel TR; Fei B; Madhuranthakam AJ; Maldjian JA Neuro Oncol; 2020 Mar; 22(3):402-411. PubMed ID: 31637430 [TBL] [Abstract][Full Text] [Related]
14. Predicting IDH mutation status in grade II gliomas using amide proton transfer-weighted (APTw) MRI. Jiang S; Zou T; Eberhart CG; Villalobos MAV; Heo HY; Zhang Y; Wang Y; Wang X; Yu H; Du Y; van Zijl PCM; Wen Z; Zhou J Magn Reson Med; 2017 Sep; 78(3):1100-1109. PubMed ID: 28714279 [TBL] [Abstract][Full Text] [Related]
15. Diagnostic accuracy and potential covariates for machine learning to identify IDH mutations in glioma patients: evidence from a meta-analysis. Zhao J; Huang Y; Song Y; Xie D; Hu M; Qiu H; Chu J Eur Radiol; 2020 Aug; 30(8):4664-4674. PubMed ID: 32193643 [TBL] [Abstract][Full Text] [Related]
16. Non-invasive prediction of IDH-wildtype genotype in gliomas using dynamic Vettermann F; Suchorska B; Unterrainer M; Nelwan D; Forbrig R; Ruf V; Wenter V; Kreth FW; Herms J; Bartenstein P; Tonn JC; Albert NL Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2581-2589. PubMed ID: 31410540 [TBL] [Abstract][Full Text] [Related]
17. [Mutation of isocitrate dehydrogenase gene in Chinese patients with glioma]. Pan Y; Qi XL; Wang LM; Dong RF; Zhang M; Zheng DF; Chang Q; Zhong YF Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):292-8. PubMed ID: 24004584 [TBL] [Abstract][Full Text] [Related]
18. Predicting Isocitrate Dehydrogenase (IDH) Mutation Status in Gliomas Using Multiparameter MRI Radiomics Features. Peng H; Huo J; Li B; Cui Y; Zhang H; Zhang L; Ma L J Magn Reson Imaging; 2021 May; 53(5):1399-1407. PubMed ID: 33179832 [TBL] [Abstract][Full Text] [Related]
19. Diffuse gliomas in patients aged 55 years or over: A suggestion for IDH mutation testing. Barresi V; Eccher A; Simbolo M; Cappellini R; Ricciardi GK; Calabria F; Cancedda M; Mazzarotto R; Bonetti B; Pinna G; Sala F; Ghimenton C; Scarpa A Neuropathology; 2020 Feb; 40(1):68-74. PubMed ID: 31758617 [TBL] [Abstract][Full Text] [Related]
20. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients. Mukasa A; Takayanagi S; Saito K; Shibahara J; Tabei Y; Furuya K; Ide T; Narita Y; Nishikawa R; Ueki K; Saito N Cancer Sci; 2012 Mar; 103(3):587-92. PubMed ID: 22136423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]